Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet : An efficiency strategy;Traitement de l'hyperparathyroïdie secondaire, résistante aux thérapeutiques conventionnelles, et de l'hyperparathyroïdie tertiaire par le cinacalcet : une stratégie efficace

Nephrologie et Therapeutique

Volumn 6, Issue 2, 2010, Pages 105-110

  Jean, Guillaume ^a   Vanel, Thierry ^a   Terrat, Jean Claude ^a   Hurot, Jean Marc ^a   Lorriaux, Christie ^a   Mayor, Brice ^a   Deleaval, Patrick ^a   Vovan, Cyril ^a   Chazot, Charles ^a  

^a Centre de Rein Artificiel de Tassin   (France)

Author keywords

Cinacalcet; Haemodialysis; Hyperparathyroidism; Mineral metabolism; Vitamin D

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CALCIUM CARBONATE; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; VITAMIN D;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; SECONDARY HYPERPARATHYROIDISM; TERTIARY HYPERPARATHYROIDISM; TREATMENT RESPONSE;

ADULT; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHELATING AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; VITAMIN D;

EID: 77950595714     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.12.004     Document Type: Article

References (37)

1. Young E.W., Akiba T., Albert J.M., McCarthy J.T., Kerr P.G., Mendelssohn D.C., et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 44 (2004) 34-38
2. Eknoyan G., Levin A., and Levin N.W. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (2003) 1-201
3. Block G.A., Martin K.J., de Francisco A.L., Turner S.A., Avram M.M., Suranyi M.G., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 (2004) 1516-1525
4. Goodman W.G., Frazao J.M., Goodkin D.A., Turner S.A., Liu W., and Coburn J.W. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58 (2000) 436-445
5. Goodman W.G., Hladik G.A., Turner S.A., Blaisdell P.W., Goodkin D.A., Liu W., et al. The calcimimetic agent amg 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 (2002) 1017-1024
6. Strippoli G.F., Palmer S., Tong A., Elder G., Messa P., and Craig J.C. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47 (2006) 715-726
7. Moe S.M., Chertow G.M., Coburn J.W., Quarles L.D., Goodman W.G., Block G.A., et al. Achieving nkf-k/doqi bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 67 (2005) 760-771
8. Drueke T.B., and Ritz E. Treatment of secondary hyperparathyroidism in ckd patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 4 (2009) 234-241
9. Messa P., Macario F., Yaqoob M., Bouman K., Braun J., von Albertini B., et al. The optima study: assessing a new cinacalcet (sensipar/mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 (2008) 36-45
10. Cunningham J., Danese M., Olson K., Klassen P., and Chertow G.M. Effects of the calcimimetic cinacalcet hcl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (2005) 1793-1800
11. Urena Torres P. Clinical experience with cinacalcet HCL. Nephrol Dial Transplant 19 Suppl 5: (2004) V27-V33
12. Lien Y.H., Silva A.L., and Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 20 (2005) 1232-1237
13. Chertow G.M., Pupim L.B., Block G.A., Correa-Rotter R., Drueke T.B., Floege J., et al. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2 (2007) 898-905
14. KDIGO C.M. Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76 (2009) S1-130
15. St Peter W.L., Li Q., Liu J., Persky M., Nieman K., Arko C., et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4 (2009) 354-360
16. Urena P., Jacobson S.H., Zitt E., Vervloet M., Malberti F., Ashman N., et al. Cinacalcet and achievement of the nkf/k-doqitm recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Nephrol Dial Transplant (2009)
17. Fishbane S., Shapiro W.B., Corry D.B., Vicks S.L., Roppolo M., Rappaport K., et al. Cinacalcet hcl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 3 (2008) 1718-1725
18. Touam M., Menoyo V., Attaf D., Thebaud H.E., and Drueke T.B. High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney Int 67 (2005) 2065 [2065-2066; author reply]
19. Sterrett J.R., Strom J., Stummvoll H.K., Bahner U., Disney A., Soroka S.D., et al. Cinacalcet HCL (sensipar/mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68 (2007) 10-17
20. Yano S., Suzuki K., Sumi M., Tokumoto A., Shigeno K., Himeno Y., et al. Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism. J Bone Miner Metab (2009)
21. Valle C., Rodriguez M., Santamaria R., Almaden Y., Rodriguez M.E., Canadillas S., et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 19 (2008) 2430-2436
22. Block G.A., Zeig S., Sugihara J., Chertow G.M., Chi E.M., Turner S.A., et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23 (2008) 2311-2318
23. Schaefer R.M., Bover J., Dellanna F., Sanz D., Asensio C., Sanchez Gonzalez M.C., et al. Efficacy of cinacalcet administered with the first meal after dialysis: the Sensor study. Clin Nephrol 70 (2008) 126-134
24. Malluche H.H., Monier-Faugere M.C., Wang G., Fraza O.J., Charytan C., Coburn J.W., et al. An assessment of cinacalcet HCL effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69 (2008) 269-278
25. Jean G., Chazot C., and Charra B. Twelve months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 68 (2007) 63-64
26. Jean G., Chazot C., and Charra B. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Nephrol Dial Transplant 22 (2007) 2102-2103
27. McKenna M.J. Differences in vitamin D status between countries in young adults and the elderly. Am J Med 93 (1992) 69-77
28. Menon S., Valentini R.P., Hidalgo G., Peschansky L., and Mattoo T.K. Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23 (2008) 1831-1836
29. Brown S.E. Vitamin D and fracture reduction: an evaluation of the existing research. Altern Med Rev 13 (2008) 21-33
30. Schwartz G.G. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol 19 (2009) 96-102
31. Bikle D.D. Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep 7 (2009) 58-63
32. Danescu L.G., Levy S., and Levy J. Vitamin D and diabetes mellitus. Endocr J 35 (2009) 11-17
33. Bikle D.D. Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens 17 (2008) 348-352
34. Pilz S., Marz W., Wellnitz B., Seelhorst U., Fahrleitner-Pammer A., Dimai H.P., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93 (2008) 3927-3935
35. Holick M.F. Vitamin D deficiency. N Engl J Med 357 (2007) 266-281
36. Jean G., Souberbielle J.C., and Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant (2009)
37. Jean G., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: Evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 110 (2008) c58-c65